1.91 USD
▲+0.10+3.24%
盘后 1.88 +1.62%
2026-08-03
市值
$50.78M
市盈率
—
EPS
-1.61
股息率
—
52 周区间
1.09 – 2.96
成交量
414.34K
Beta
0.89
目标价
7.00
52W 低 1.0952W 高 2.96
价格走势
公司简介
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen...